Viviani Lucas G, Iijima Thais S, Piccirillo Erika, Rezende Leandro, Alegria Thiago G P, Netto Luis Eduardo S, T-do Amaral Antonia, Miyamoto Sayuri
Department of Biochemistry, Institute of Chemistry, University of São Paulo, Av. Prof. Lineu Prestes 748, 05508-000 São Paulo, Brazil.
Center for Medicinal Chemistry (CQMED), State University of Campinas, Av. André Tosello 550, 13083-886 Campinas, Brazil.
J Med Chem. 2025 Jan 9;68(1):307-323. doi: 10.1021/acs.jmedchem.4c01884. Epub 2024 Dec 19.
The human 15-lipoxygenase-2 (h15-LOX-2) catalyzes mainly the regio- and stereospecific oxygenation of arachidonate to its corresponding hydroperoxide (15()-HpETE). h15-LOX-2 is implicated in the biosynthesis of inflammatory lipid mediators and plays a role in the development of atherosclerotic plaques, but it is still underexploited as a drug target. Here, to search for novel h15-LOX-2 inhibitors, we used a virtual screening (VS) approach consisting of shape-based matching, two-dimensional (2D) structural "dissimilarity", docking, and visual inspection filters, which were applied to a "curated" ZINC database (∼8 × 10 compounds). The VS was experimentally validated, and six micromolar-range inhibitors were identified among 13 tested compounds (46.2%). The values could be determined for two inhibitors, compounds ( = 16.4 ± 8.1 μM) and ( = 15.1 ± 7.6 μM), which showed a mixed-type mechanism of inhibition. Overall, the identified inhibitors fulfill drug-like criteria and are structurally novel compared with known h15-LOX-2 inhibitors.
人15-脂氧合酶-2(h15-LOX-2)主要催化花生四烯酸区域和立体特异性氧化生成相应的氢过氧化物(15-(S)-HpETE)。h15-LOX-2参与炎症脂质介质的生物合成,并在动脉粥样硬化斑块的形成中起作用,但作为药物靶点仍未得到充分开发。在此,为了寻找新型h15-LOX-2抑制剂,我们采用了虚拟筛选(VS)方法,该方法包括基于形状的匹配、二维(2D)结构“差异”、对接和视觉检查筛选,应用于一个“精选的”ZINC数据库(约8×10⁶种化合物)。VS经过实验验证,在13种测试化合物中鉴定出6种微摩尔级抑制剂(46.2%)。可以确定两种抑制剂化合物1(IC₅₀ = 16.4 ± 8.1 μM)和化合物2(IC₅₀ = 15.1 ± 7.6 μM)的IC₅₀值,它们表现出混合型抑制机制。总体而言,所鉴定的抑制剂符合类药标准,与已知的h15-LOX-2抑制剂相比结构新颖。